Advisors Asset Management Inc. Acquires New Position in Eli Lilly and Company $LLY

Eli Lilly and Company logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Advisors Asset Management opened a position in Eli Lilly, buying 70,191 shares worth about $81.2 million in the third quarter. The stock now represents 0.7% of the firm’s portfolio and is its 22nd-largest holding.
  • Other investment firms also increased or initiated positions, and institutional investors collectively own 82.53% of Lilly’s shares.
  • Lilly reported quarterly EPS of $7.48, beating the $5.71 estimate, while revenue rose 38.6% year over year to $24.4 billion. Analysts’ consensus rating is Moderate Buy, with an average target price of $1,422.
  • MarketBeat previews the top five stocks to own by December 1st.

Advisors Asset Management Inc. bought a new position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) during the third quarter, according to the company in its most recent disclosure with the SEC. The firm bought 70,191 shares of the company's stock, valued at approximately $81,217,000. Eli Lilly and Company comprises 0.7% of Advisors Asset Management Inc.'s holdings, making the stock its 22nd largest holding.

Several other hedge funds also recently made changes to their positions in the company. Coastal Bridge Advisors LLC acquired a new position in Eli Lilly and Company during the 2nd quarter valued at approximately $2,959,000. Birinyi Associates Inc. grew its stake in Eli Lilly and Company by 32.6% during the 3rd quarter. Birinyi Associates Inc. now owns 1,460 shares of the company's stock worth $1,689,000 after buying an additional 359 shares during the last quarter. Bridges Investment Management Inc. grew its stake in Eli Lilly and Company by 38.5% during the 3rd quarter. Bridges Investment Management Inc. now owns 35,294 shares of the company's stock worth $40,838,000 after buying an additional 9,815 shares during the last quarter. Bernicke Wealth Management Ltd. acquired a new stake in Eli Lilly and Company in the third quarter worth $5,001,000. Finally, Mosaic Family Wealth Partners LLC increased its position in Eli Lilly and Company by 70.6% in the second quarter. Mosaic Family Wealth Partners LLC now owns 3,455 shares of the company's stock worth $4,144,000 after buying an additional 1,430 shares during the period. Institutional investors and hedge funds own 82.53% of the company's stock.

More Eli Lilly and Company News

These are some of the LLY news items that stood out recently:

  • Positive Sentiment: Some Wall Street commentary remains bullish: Jefferies reportedly has the highest price target among analysts, and Barclays recently raised its target while maintaining an Overweight rating. Jefferies has Wall Street’s highest target on Eli Lilly
  • Neutral Sentiment: Lilly’s 2026 acquisition spending has surpassed $32 billion, including deals aimed at building cancer and immunology capabilities. The investments could strengthen future growth but also raise execution and capital-allocation questions. Lilly buying spree surpasses $32 billion
  • Negative Sentiment: Valuation remains a key concern: commentary described Lilly’s roughly $1.4 trillion valuation as dependent on substantial future growth, while another analysis questioned whether shares near record highs still offer attractive upside. This may make the stock vulnerable to profit-taking or any disappointment. Eli Lilly’s $1.4 trillion valuation is heavy with hope

Insider Buying and Selling

In other Eli Lilly and Company news, EVP Anat Hakim sold 5,000 shares of the stock in a transaction on Monday, November 2nd. The stock was sold at an average price of $1,402.52, for a total transaction of $7,012,600.00. Following the completion of the transaction, the executive vice president directly owned 4,137 shares of the company's stock, valued at approximately $5,802,225.24. This trade represents a 54.72% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.14% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of research firms have issued reports on LLY. China Merchants Securities cut Eli Lilly and Company from a "buy" rating to a "hold" rating in a research note on Thursday, November 12th. TD Cowen restated a "buy" rating and set a $1,250.00 price target on shares of Eli Lilly and Company in a research report on Tuesday, September 22nd. Bank of America reaffirmed a "buy" rating and issued a $1,497.00 price objective on shares of Eli Lilly and Company in a report on Friday, October 30th. Morgan Stanley lifted their price objective on shares of Eli Lilly and Company from $1,430.00 to $1,596.00 and gave the company an "overweight" rating in a research report on Friday, October 30th. Finally, Sanford C. Bernstein reiterated an "outperform" rating and issued a $1,450.00 price objective on shares of Eli Lilly and Company in a research report on Monday, October 26th. One analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $1,422.00.

Read Our Latest Stock Analysis on Eli Lilly and Company

Eli Lilly and Company Stock Down 2.2%

Shares of Eli Lilly and Company stock opened at $1,352.18 on Friday. The company has a debt-to-equity ratio of 1.17, a current ratio of 1.39 and a quick ratio of 1.00. Eli Lilly and Company has a 1-year low of $850.51 and a 1-year high of $1,475.25. The business's fifty day moving average price is $1,263.45 and its two-hundred day moving average price is $1,117.53. The company has a market capitalization of $1.27 trillion, a P/E ratio of 43.89, a PEG ratio of 1.65 and a beta of 0.40.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings results on Thursday, October 29th. The company reported $7.48 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.71 by $1.77. The company had revenue of $24.40 billion during the quarter, compared to analysts' expectations of $22.58 billion. Eli Lilly and Company had a return on equity of 86.76% and a net margin of 31.90%. The company's revenue for the quarter was up 38.6% compared to the same quarter last year. During the same quarter in the prior year, the business posted $7.02 earnings per share. As a group, research analysts forecast that Eli Lilly and Company will post 35.70 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, December 10th. Investors of record on Friday, November 13th will be paid a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.5%. The ex-dividend date is Friday, November 13th. Eli Lilly and Company's dividend payout ratio (DPR) is currently 22.46%.

About Eli Lilly and Company

(Free Report)

Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for people and animals. Its work spans areas including diabetes and obesity, cancer, immunology, neuroscience and pain management. The company's medicines include treatments for diabetes and obesity, such as Mounjaro and Zepbound, as well as products for cancer and other conditions. Lilly also conducts research into new medicines and invests in the development of treatments across its therapeutic areas.

See Also

Institutional Ownership by Quarter for Eli Lilly and Company (NYSE:LLY)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Eli Lilly and Company Right Now?

Before you consider Eli Lilly and Company, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.

While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Related Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines